Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
November 10, 2021
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for joining us for the business update and earnings call for the third quarter of 2021. As was noted, on the line with me today are our CFO, Lisa Delfini, and Bill Forbes, who serves as our Chief Development Officer. Lisa and I have some remarks ready, and after that, all three of us will take questions. With the year winding down, we're thrilled to report how enrollment has been going in both of our trials. I'll provide a little extra detail about that progress and about how we're getting ready for the upcoming development stages. Our most advanced clinical program is aimed at treating severe chronic itching in people who have prurigo nodularis, or PN. This is a significant and disabling illness characterized by bumps and nodules appearing on the skin, accompanied by unyielding and intense scratching sensations. To date, nothing has received approval to treat this condition. PN is a long-term neuro-inflammatory disorder, and because patients scratch continuously, they become stuck in a repetitive scratching loop that proves very difficult to escape. That persistent scratching causes papules and nodules to continually develop and spread, worsening across the patient's body. We put the worldwide number of PN sufferers at approximately 730,000 individuals — 300,000 located in the United States, and 430,000 across the remainder of the globe. We believe in what our mechanism of action can achieve and how useful it could be for syndication, along with the benefits that come from being an oral candidate in late-stage development. That combination provides a major competitive advantage and a potentially valuable choice for patients in an area where biologics make up the majority of compounds being developed. At present, we're conducting a Phase 2b/3 study for this condition, known as our PRISM trial. Enrollment for the PRISM trial is happening across the U.S. and Europe, and more than 60 sites are active as of today. For this trial, the main measure we're looking at is a responder analysis — meaning a subject needs to show a drop of four points from where they started, based on the Worst Itch Numerical Rating Scale. The study is blinded and involves 14 weeks of treatment. Out of the 360 subjects we planned for, we've now randomized roughly 90%, so we're thrilled to be wrapping up enrollment soon and moving closer to seeing top line data. The share of subjects who keep going into the open-label extension is still high, also around 90%. That gives us not just long term safety information, but also valuable efficacy findings related to skin healing and quality of life for these participants. We think that if you go after the symptomatic endpoint — bringing it down — a therapy that works could potentially break the itch scratch cycle, which would let the skin heal and, over time, produce disease modification. At certain sites in the study, we're taking photographs, and we keep hearing positive anecdotes from patients on long-term therapy who, we know, are on drug in our open-label extension. Also, an investigator-initiated trial is going on in Germany that follows patients after they've completed 12 months of Haduvio treatment, to determine whether the itching returns. After therapy stops, these individuals will be monitored by researchers for 1 year, with a look at itch recurrence, how much concomitant medication is used, and overall skin health. For clinicians, this offers important information about the way the itch-scratch cycle is broken, how healing unfolds across various body areas, and how long those gains last. Turning to our second clinical program, it addresses chronic cough tied to Idiopathic Pulmonary Fibrosis, also known as IPF. This condition is serious and worsens over time, marked by scarring within lung tissue. One of the most troubling symptoms patients face is persistent coughing, which affects somewhere between 70% and 85% of them, and there are currently no approved therapies for it. In the United States, we put the number of IPF patients at approximately 130,000, and Europe has a similar figure. Given the elevated five-year mortality tied to IPF, those prescribing and those suffering from it seek not just to decelerate disease progression but equally to enhance quality of life. Furthermore, chronic cough with IPF represents one indication within a far broader chronic cough opportunity, spanning other interstitial lung diseases along with the expanding prospects in refractory chronic cough. Should we obtain positive IPF cough data, both markets are ones we would evaluate for additional clinical development. We are running a Phase 2, double-blind crossover trial featuring a 14 day washout between every three week treatment arm. The primary endpoint being assessed is mean percent change in daytime cough frequency relative to baseline. A digital cough monitor captures daytime cough frequency when comparing treatment versus placebo arms; this study is presently underway in the U.K., and owing to the lung impairment tied to this condition, it has faced greater disruption from COVID-19 restrictions than our PN study did. Nevertheless, those restrictions loosened during the summer and have stayed that way. The design calls for enrolling roughly 60 subjects, aiming for 44 completers. We have reactivated 10 among our 15 target U.K. sites; it's encouraging to see them screening and rolling in participants; steady activity has been observed, carrying into November; we'll keep collaborating closely with the rest of our qualified U.K. sites so they too can start enrolling. Expected top line data from this trial should arrive during the first half of next year. A highly significant stretch of clinical data lies just ahead for our company. Within the coming months, we anticipate finishing enrollment across both the PN and IPF cough studies and reporting results from each. These indications represent substantial market opportunities, and the chance for expanding into additional indications across both pruritus and chronic cough is considerable. Beyond our work to finish the trials, the team has been busy getting ready for the next phase of development in both of these indications, and also assessing other possible indications for future development; we're also actively sharing our data and taking part in conferences. During the last few months, we joined pulmonary fibrosis awareness month in September, together with action for pulmonary fibrosis. We also went to fall clinical in Las Vegas, the 11th World Congress on Itch, which was held virtually, and Bill gave a talk on a panel discussion, and we took part in the Bio Europe conference. So things have been hectic at Trevi. That covers everything I have for the business update this quarter. I'll now hand it to Lisa to go over our financial results, and after that we'll open the line for questions. Lisa?
Lisa Delfini
executiveThanks, Jennifer, and good afternoon, everybody. Just a quick note that you can find the complete financial results for the 3 and 9 months that ended on September 30, 2021, in the press release we put out before this call, as well as in our 10-Q, which was filed with the SEC earlier today once the market had closed. For Q3 of 2021, our net loss came in at $7.3 million, versus a net loss of $7.4 million during the comparable quarter of 2020. R&D expenses totaled $4.7 million in the third quarter of 2021, down from $4.8 million in that same period of 2020. The main driver there was fewer purchases of clinical trial supplies as our trials approach completion, though that was partly offset by higher personnel related expenses stemming from growth in our R&D employee headcount. G&A expenses came to $2.2 million in the third quarter of 2021, compared with $2.4 million in the equivalent period of 2020; the primary reason was reduced market research costs and a lower stock based compensation expense, partly offset by greater legal and other professional fees. Other expenses also rose by roughly $161,000, which reflects a full quarter of interest expense tied to our term loan with SVB that was executed in August of 2020. At September 30, 2021, our cash and cash equivalents came to $29.3 million, versus $45 million at December 31, 2020. After the quarter ended, we brought in $14.8 million by selling common stock and warrants to a new investor as well as to NEA, an existing investor that also elected to take part. Those proceeds will go toward funding the development of Haduvio and company operations; that wraps up our prepared remarks. I'll hand the call back to the operator now for Q&A.
Nick Rubino
analystNick Rubino here, filling in for Annabel — thanks for taking our question. We're simply attempting to gauge what to expect from the PRISM readout coming up. So you've made a number of changes, with the hope of bettering the PRISM design relative to Phase 2 — is the benchmark the Phase 2 findings, where a 15% delta in the MITT and a 30% delta in the Completer groups were observed? Or do you hold higher expectations for the responder percentage regarding the four point reduction? And then, on a separate note, where does LID stand at present? Thank you.
Jennifer Good
executiveBill, I'll let you handle the PRISM response, and after that I'll weigh in on LID.
Bill Forbes
executiveAlright, hi Nick. It’s Bill here, and I appreciate the questions. So, clearly an interim analysis was carried out — however, that work was handled by a statistician who is independent. Therefore, if we’re discussing sample size, our estimation was done on PRISM. Naturally, we aren’t aware of what those findings showed; they landed in a conditional power zone that looked promising, as defined in the protocol. Given that, we have confidence the trial kept performing as it had been — that the PRISM study, in its current design and with its current power, ought to yield positive results according to that interim analysis. So I’m not sure whether that addresses what you asked, Nick, regarding the sort of gap between active and placebo.
Nick Rubino
analystYeah, that really does help a lot.
Bill Forbes
executiveSo then, regarding what you gave us, it was sort of a Phase 2 view of what we observed; as far as — Bill Forbes (A): Oh, you mean the earlier study?
Nick Rubino
analystYes.
Bill Forbes
executiveYeah. No, what I'm saying is, I suppose, when you look at it, for this specific trial — an earlier one involved slightly more than 60 patients across three arms, and clearly the one we're running now has 360 patients split between two arms. Clearly, we're feeling fairly confident that we have the statistical power required to demonstrate a separation between the active drug and placebo here, given what those findings showed; so — based on that earlier trial; so clearly, right now it comes down to how well we execute, and I can share that the sites are eager to bring this trial to completion. I mean, October was quite strong for them, and the screenings during November have looked really solid. So our hope is that we can keep pushing forward on this and reach the point where we analyze the data, and clearly, there's a 14 week double-blind window involved. So that explains why we're saying we lean toward reading out results at some point during the first half of next year.
Jennifer Good
executiveThank you. Nick, that was the kind of question about seeing into the future that all of us put to Bill each week. Sadly, he has no idea, though I'm happy you brought it up. Regarding your question about LID, that's something we remain rather intrigued by. We hold the intellectual property rights for it. As we've conveyed, our attention is on those 2 indications. Based on what the data shows — and in both cases we've examined additional chances to grow in pruritus and cough, plus the LID possibility — I believe a solid strategic choice will emerge once we have final results from both trials, determining where we go next and what we're able to take on and pay for. So I'd say it remains a possibility, though it will be weighed against other prospects in the pruritus and cough area too.
Rohit Bhasin
analystRobert here, filling in for Serge. Appreciate you taking the question. How do you view the two recent picks along with the Phase 3 data in PN, and where does that product slot into the PN treatment paradigm?
Jennifer Good
executiveYeah, fair question. We did review those results. My habit is generally to avoid weighing in on other companies. The positive side, I'd say, is that this is a hard condition. They achieved statistical significance, which clearly benefits patients. I mean, everyone recognizes how to choose them, so it's a solid drug and they've executed well with it. Still, the findings weren't so intimidating that I'd call them unbeatable, so to speak. So I see that as a solid opening for us; this market has turned fairly biologics-oriented and trend-driven; my personal take, and this is just my own view, is that I was pleased the drug works, yet equally pleased the results weren't overpowering. Because that, I believe, leaves us well positioned as an oral therapy within that treatment paradigm. So naturally we're focused on how we move through therapy toward the biologics. But that will hinge on our own data and our own label before we can do so.
Rohit Bhasin
analystAs a quick follow-up, did enrollment for the PRISM trial get impacted in any way by the dupixent trial?
Jennifer Good
executiveDupixent wasn't really the issue, since they ran many sites across various nations — China, Russia, sort of throughout Europe — and we overlap with them at a handful of locations; so I wouldn't claim dupixent hit us very hard. My understanding is their second trial has wrapped up enrollment, so they're no longer in the picture. Still, our paths didn't cross with theirs very often out in the field.
Jennifer Good
executiveEveryone, thank you for joining us on today's call. Our gratitude also goes out to the team at Trevi, the investigators on our studies, and every subject still taking part in our clinical trials; over the coming 3 months we'll be attending a number of conferences, beginning with the Stifel Healthcare conference next week. We look forward to seeing you there. Thanks.
Operator
operatorThanks. That brings an end to the conference call for today, and we appreciate everyone for joining us for today's presentation. You're welcome to disconnect your lines, and have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.